相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model
Melvin M. Evers et al.
MOLECULAR THERAPY (2018)
Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease A Randomized Clinical Trial
Michael S. Rafii et al.
JAMA NEUROLOGY (2018)
Outcomes of Interventional-MRI Versus Microelectrode Recording-Guided Subthalamic Deep Brain Stimulation
Philip S. Lee et al.
FRONTIERS IN NEUROLOGY (2018)
MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain
L. Samaranch et al.
GENE THERAPY (2017)
AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease
J. Miniarikova et al.
GENE THERAPY (2017)
Axonal transport of AAV9 in nonhuman primate brain
F. Green et al.
GENE THERAPY (2016)
Intraoperative MRI for deep brain stimulation lead placement in Parkinson's disease: 1 year motor and neuropsychological outcomes
Christos Sidiropoulos et al.
JOURNAL OF NEUROLOGY (2016)
Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease
Jill L. Ostrem et al.
JOURNAL OF NEUROSURGERY (2016)
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
Jana Miniarikova et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
C. Warren Olanow et al.
ANNALS OF NEUROLOGY (2015)
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Stephane Palfi et al.
LANCET (2014)
Axonal transport of adeno-associated viral vectors is serotype-dependent
E. A. Salegio et al.
GENE THERAPY (2013)
Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain
W. San Sebastian et al.
GENE THERAPY (2013)
Strong Cortical and Spinal Cord Transduction After AAV7 and AAV9 Delivery into the Cerebrospinal Fluid of Nonhuman Primates
Lluis Samaranch et al.
HUMAN GENE THERAPY (2013)
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus et al.
NEUROLOGY (2013)
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Richard Grondin et al.
BRAIN (2012)
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Gabriele Mittermeyer et al.
HUMAN GENE THERAPY (2012)
Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum
Waldy San Sebastian et al.
HUMAN GENE THERAPY (2012)
Deep Brain Stimulation in Area LC Controllably Triggers Auditory Phantom Percepts
Paul S. Larson et al.
NEUROSURGERY (2012)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
Peter A. LeWitt et al.
LANCET NEUROLOGY (2011)
Anterograde Axonal Transport of AAV2-GDNF in Rat Basal Ganglia
Agnieszka Ciesielska et al.
MOLECULAR THERAPY (2011)
Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease
R. Mark Richardson et al.
MOLECULAR THERAPY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates
Dali Yin et al.
NEUROIMAGE (2011)
Novel Platform for MRI-Guided Convection-Enhanced Delivery of Therapeutics: Preclinical Validation in Nonhuman Primate Brain
R. Mark Richardson et al.
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2011)
Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF
Adrian P. Kells et al.
JOURNAL OF NEUROSCIENCE (2010)
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics Laboratory investigation
Dali Yin et al.
JOURNAL OF NEUROSURGERY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors
Xiaomin Su et al.
MOLECULAR THERAPY (2010)
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Piotr Hadaczek et al.
MOLECULAR THERAPY (2010)
A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease
Shin-ichi Muramatsu et al.
MOLECULAR THERAPY (2010)
Qualitative Imaging of Adeno-Associated Virus Serotype 2-Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease
Francisco Valles et al.
NEUROSURGERY (2010)
Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys
Louisa C. Johnston et al.
HUMAN GENE THERAPY (2009)
Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
Xiaomin Su et al.
HUMAN GENE THERAPY (2009)
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
C. W. Christine et al.
NEUROLOGY (2009)
ANATOMIC COMPRESSION CAUSED By HIGH-VOLUME CONVECTION-ENHANCED DELIVERY TO THE BRAIN
Francisco Valles et al.
NEUROSURGERY (2009)
Future Applications: Gene Therapy
R. M. Richardson et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2009)
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex
Adrian P. Kells et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Controlled dissemination of AAV vectors in the primate brain
Vanja Varenika et al.
NEUROTHERAPY: PROGRESS IN RESTORATIVE NEUROSCIENCE AND NEUROLOGY (2009)
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery
Vanja Varenika et al.
JOURNAL OF NEUROSURGERY (2008)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Argonaute proteins: key players in RNA silencing
Gyorgy Hutvagner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
J. L. Eberling et al.
NEUROLOGY (2008)
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Michael G. Kaplitt et al.
LANCET (2007)
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism
Marina E. Emborg et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC
Krystof S. Bankiewicz et al.
MOLECULAR THERAPY (2006)
A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys
John R. Forsayeth et al.
MOLECULAR THERAPY (2006)
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease
Biplob Dass et al.
NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents - Technical note
MT Krauze et al.
JOURNAL OF NEUROSURGERY (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms
R Levy et al.
BRAIN (2001)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
Convection-enhanced delivery of AAV vector in parkinsonian monkeys;: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
KS Bankiewicz et al.
EXPERIMENTAL NEUROLOGY (2000)
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
A Yamamoto et al.
CELL (2000)
分享论文
